Belantamab mafodotin (Blenrep) — Clinical FAQs

Question 1

What is Belantamab mafodotin FDA-approved to treat?

Accepted Answer

Belantamab mafodotin is FDA-approved for the following oncology indications: 1. Relapsed or refractory multiple myeloma in combination with bortezomib and dexamethasone (Vd) after ≥1 prior line (re-approved November 2024; DREAMM-7 trial) 2. Relapsed or refractory multiple myeloma in combination with pomalidomide and dexamethasone (Pd) after ≥1 prior line including lenalidomide (re-approved November 2024; DREAMM-8 trial).

Question 2

How does Belantamab mafodotin work (mechanism of action)?

Accepted Answer

Belantamab mafodotin is an afucosylated humanized IgG1 anti-BCMA antibody conjugated via a non-cleavable maleimidocaproyl linker to monomethyl auristatin F (MMAF), a charged auristatin that is less membrane-permeable than MMAE, thereby reducing bystander killing. The afucosylated Fc region markedly enhances FcγRIIIa-mediated antibody-dependent cellular cytotoxicity (ADCC) by NK cells and macrophages. Upon BCMA binding and internalization, lysosomal degradation releases MMAF-containing catabolites that inhibit tubulin polymerization, inducing mitotic arrest and apoptosis. The triple mechanism of ADC-mediated direct killing, ADCC enhancement, and antibody-dependent cellular phagocytosis (ADCP) distinguishes belantamab from non-afucosylated BCMA antibodies.

Question 3

How is Belantamab mafodotin administered?

Accepted Answer

Belantamab mafodotin is administered Intravenous (IV). Administered as an IV infusion over 30 minutes.

Question 4

What are the most common side effects of Belantamab mafodotin?

Accepted Answer

The most commonly reported side effects of Belantamab mafodotin (≥10% incidence) include: Keratopathy/corneal epithelial changes (~70–80%), Blurred vision (~50%), Dry eye (~30%), Fatigue (~37%), Nausea (~28%) and others (13 total). Consult your oncologist for complete prescribing information.

Question 5

Does Belantamab mafodotin have a black box warning?

Accepted Answer

Yes. Belantamab mafodotin carries FDA black box warning(s) regarding: 1. Ocular toxicity: corneal epithelial microcyst-like changes (keratopathy) leading to visual acuity changes, including severe vision loss; mandatory slit-lamp ophthalmologic examination required before each dose; withhold for Grade ≥2 corneal changes with visual acuity impact; REMS program required

Question 6

Is Belantamab mafodotin safe during pregnancy?

Accepted Answer

Belantamab mafodotin pregnancy safety: No adequate human data. MMAF is a potent antimitotic agent expected to cause embryo-fetal harm. Women of reproductive potential must use effective contraception during and for 4 months after the last dose. Male patients with female partners of reproductive potential should use effective contraception during and for 6 months after the last dose. Breastfeeding is contraindicated during and for 4 months after the last dose.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

belantamab mafodotin — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms